Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
Glatt S, Jemec GBE, Forman S, Sayed C, Schmieder G, Weisman J, Rolleri R, Seegobin S, Baeten D, Ionescu L, Zouboulis CC, Shaw S. Glatt S, et al. Among authors: rolleri r. JAMA Dermatol. 2021 Nov 1;157(11):1279-1288. doi: 10.1001/jamadermatol.2021.2905. JAMA Dermatol. 2021. PMID: 34406364 Free PMC article. Clinical Trial.
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).
Lebwohl M, Blauvelt A, Paul C, Sofen H, Węgłowska J, Piguet V, Burge D, Rolleri R, Drew J, Peterson L, Augustin M. Lebwohl M, et al. Among authors: rolleri r. J Am Acad Dermatol. 2018 Aug;79(2):266-276.e5. doi: 10.1016/j.jaad.2018.04.013. Epub 2018 Apr 14. J Am Acad Dermatol. 2018. PMID: 29660425 Free article. Clinical Trial.
Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials.
Blauvelt A, Reich K, Lebwohl M, Burge D, Arendt C, Peterson L, Drew J, Rolleri R, Gottlieb AB. Blauvelt A, et al. Among authors: rolleri r. J Eur Acad Dermatol Venereol. 2019 Mar;33(3):546-552. doi: 10.1111/jdv.15258. Epub 2018 Oct 14. J Eur Acad Dermatol Venereol. 2019. PMID: 30242918 Free PMC article.
Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis.
Sandborn WJ, Bosworth B, Zakko S, Gordon GL, Clemmons DR, Golden PL, Rolleri RL, Yu J, Barrett AC, Bortey E, Paterson C, Forbes WP. Sandborn WJ, et al. Among authors: rolleri rl. Gastroenterology. 2015 Apr;148(4):740-750.e2. doi: 10.1053/j.gastro.2015.01.037. Epub 2015 Jan 30. Gastroenterology. 2015. PMID: 25644096 Free article. Clinical Trial.
Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta™) tablets in nondependent recreational opioid users.
Schoedel KA, Rolleri RL, Faulknor JY, Pixton GC, Chen N, Bass A, Sommerville KW, Sellers E. Schoedel KA, et al. Among authors: rolleri rl. J Opioid Manag. 2012 Sep-Oct;8(5):315-27. doi: 10.5055/jom.2012.0131. J Opioid Manag. 2012. PMID: 23247908 Clinical Trial.
A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity.
Khanna R, Zou G, D'Haens G, Feagan BG, Sandborn WJ, Vandervoort MK, Rolleri RL, Bortey E, Paterson C, Forbes WP, Levesque BG. Khanna R, et al. Among authors: rolleri rl. Aliment Pharmacol Ther. 2015 Jan;41(1):77-86. doi: 10.1111/apt.13001. Epub 2014 Oct 27. Aliment Pharmacol Ther. 2015. PMID: 25348809 Free article. Clinical Trial.
Randomized, double-blind, placebo-controlled and active-controlled study to assess the relative abuse potential of oxycodone HCl-niacin tablets compared with oxycodone alone in nondependent, recreational opioid users.
Webster LR, Rolleri RL, Pixton GC, Sommerville KW. Webster LR, et al. Among authors: rolleri rl. Subst Abuse Rehabil. 2012 Aug 17;3:101-13. doi: 10.2147/SAR.S33080. eCollection 2012. Subst Abuse Rehabil. 2012. PMID: 24474870 Free PMC article.
Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A, Stark JG, Pixton GC, Sommerville KW, Zamora CA, Leibowitz M, Rolleri R. Bass A, et al. Among authors: rolleri r. Clin Ther. 2012 Jul;34(7):1601-12. doi: 10.1016/j.clinthera.2012.05.009. Epub 2012 Jun 19. Clin Ther. 2012. PMID: 22717418 Clinical Trial.
13 results